


(19)



(11)

EP 3 307 781 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:

A61K 31/166 ^(2006.01) **A61K 31/426** ^(2006.01)
A61P 43/00 ^(2006.01) **C07K 16/28** ^(2006.01)
G01N 33/68 ^(2006.01)

(48) Corrigendum issued on:

02.12.2020 Bulletin 2020/49

(86) International application number:

PCT/US2016/037082

(45) Date of publication and mention of the grant of the patent:

28.10.2020 Bulletin 2020/44

(87) International publication number:

WO 2016/201368 (15.12.2016 Gazette 2016/50)

(21) Application number: **16733251.9**

(22) Date of filing: **10.06.2016**

(54) **ANTIBODIES, COMPOUNDS AND SCREENS FOR IDENTIFYING AND TREATING CACHEXIA OR PRE-CACHEXIA**

ANTIKÖRPER, VERBINDUNGEN UND TESTS ZUR IDENTIFIZIERUNG UND BEHANDLUNG VON KACHEXIE ODER PRÄKACHEXIE

ANTICORPS, COMPOSÉS ET ÉCRANS PERMETTANT L'IDENTIFICATION ET LE TRAITEMENT LA CACHEXIE OU PRÉ-CACHEXIE

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(72) Inventors:

- **THOMAS, David, K.**
Brookline, MA 02446 (US)
- **GOLUB, Todd, R.**
Newtown, MA 02464 (US)

(30) Priority: **10.06.2015 US 201562173901 P**
10.06.2015 US 201562173908 P
19.06.2015 US 201562182140 P
16.07.2015 US 201562193516 P

(74) Representative: **Plasseraud IP**
66, rue de la Chaussée d'Antin
75440 Paris Cedex 09 (FR)

(43) Date of publication of application:

18.04.2018 Bulletin 2018/16

(56) References cited:

WO-A1-2010/019656 WO-A1-2011/042548
WO-A1-2015/085097 WO-A2-2007/109747

(60) Divisional application:

20196326.1

- **MORLEY JOHN E ET AL: "Cachexia: pathophysiology and clinical relevance", THE AMERICAN JOURNAL OF CLINICAL NUTRITION, AMERICAN SOCIETY FOR NUTRITION, US, vol. 83, no. 4, 1 April 2006 (2006-04-01), pages 735-743, XP007913220, ISSN: 0002-9165**

(73) Proprietors:

- **The Broad Institute, Inc.**
Cambridge, MA 02142 (US)
- **Dana-Farber Cancer Institute, Inc.**
Boston, MA 02215 (US)

EP 3 307 781 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- SPARVERO LOUIS J ET AL: "RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, LONDON, GB, vol. 7, no. 1, 17 March 2009 (2009-03-17), page 17, XP021050751, ISSN: 1479-5876, DOI: 10.1186/1479-5876-7-17
- LECLERC E ET AL: "Binding of S100 proteins to RAGE: An update", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1793, no. 6, 1 June 2009 (2009-06-01) , pages 993-1007, XP026151996, ISSN: 0167-4889, DOI: 10.1016/J.BBAMCR.2008.11.016 [retrieved on 2008-12-11]